Devices, digital health, and the technology changing how care is delivered.
Amid a bustling fundraising week for biotechs, the U.K.’s RQ Bio is adding $115 million to its coffers to advance a long-acting antibody for flu prevention.
Irish CRO giant Icon this week made Microsoft its technology partner as the organization advances its plan to increase investment in AI over the next three years. Microsoft’s Copilot and data infrastructure will be implemented enterprise-wide to further scale Icon’s agentic AI platform, Orbis.
Ionis Pharmaceuticals has offloaded regional rights to its near-approval rare disease asset zilganersen, pocketing $30 million upfront from Recordati for an ex-U.S. license to the drug candidate.
The FDA has sent an End of Enforcement notice to consumer wearable device company Whoop, putting a formal end to the agency’s investigation into its blood pressure tech use.
TechBio outfit Immunai is continuing its parade of Big Pharma partnerships with its third such pact this year, this time with German drugmaker Boehringer Ingelheim.
Dr. Israel Lowy remembers the days when he and his oncology immunotherapy colleagues were assigned tables in the distant east wing of the American Society of Clinical Oncology conference in Chicago. They would watch aficionados walk by, scoffing at these iconoclastic researchers pushing an alternative way to treat cancer.
In a recent interview with Fierce, Fosun Pharma co-president, Xinli Wang, M.D., Ph.D., detailed how the company leveraged two recent deals to quickly build up its portfolio in Alzheimer’s disease as part of a multi-step roadmap to establish its independent capabilities in the U.S.
Puerto Rico is building on its pharma manufacturing legacy to attract advanced therapy developers seeking scale, regulatory alignment and speed.
Upon finally reaching the clinic, iBio feels vindicated about the artificial intelligence-powered discovery platform it picked up in 2022.
EMD Serono, Merck KGaA’s North American healthcare arm, has promoted from within to replace its retiring head of global commercial strategy, Andrew Paterson. Taking the commercial wheel is Miguel Fernández Alcalde, who’s spent over a decade at the company.
Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, dubbed “007,” next year.
Before a biotech deal gets signed, companies are already being tested by investors, pharma partners and their own pipelines. This episode looks at the pressure, timing and hard choices shaping what makes it to the table.
Biogen isn’t wasting any time integrating its multibillion-dollar purchase of Apellis, revealing plans to part ways with some of the biotech’s staffers and halt work on most of its research programs.
Epicrispr Biotechnologies has used its gene silencing tech to boost muscle mass in three patients with facioscapulohumeral muscular dystrophy, a clinical first for the debilitating disease with no approved treatments.
HeartBeam, the maker of a cable-free ECG system, moved CEO Robert Eno into a consulting role as part of a corporate restructuring aimed at expanding the company’s global market reach.